Physician profile
Anna Levin
NPI 1255621496
$4,931.36
in general payments reported to CMS, 2019-2025
27 companies · $1,133 in 2025
The $1,133 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $873 · 2020: $161 · 2021: $206 · 2022: $455 · 2023: $927 · 2024: $1,176 · 2025: $1,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,157 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,156.72 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,513.49 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $890.98 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Incyte Corporation | $363.56 | 2022-2024 | Opzelura |
| Pfizer INC. | $255.71 | 2019-2025 | |
| Ucb, INC. | $218.19 | 2019-2024 | Bimzelx |
| Genzyme Corporation | $209.51 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $185.97 | 2019-2025 | Dupixent |
| Leo Pharma INC. | $160.16 | 2022-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $136.37 | 2023-2025 | Tremfya, Simponi, Stelara |
| Amgen INC. | $129.36 | 2023-2025 | Otezla, Otezla |
| Organon LLC | $125.74 | 2024-2025 | Hadlima, Vtama |
| E.R. Squibb & Sons, L.L.C. | $115.75 | 2023-2024 | Sotyktu |
| Lilly USA, LLC | $100.82 | 2019-2025 | Ebglyss, Taltz |
| Novartis Pharmaceuticals Corporation | $81.48 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prugen, INC. Pharmaceuticals | $72.09 | 2019 | |
| Galderma Laboratories, L.P. | $62.38 | 2019-2025 | Aklief |
| Celgene Corporation | $51.65 | 2019 | |
| Merck Sharp & Dohme LLC | $28.98 | 2019 | |
| Elite Orthopedics, LLC | $25.99 | 2025 | |
| Welch Allyn | $24.38 | 2021 | |
| Sensus Healthcare, INC. | $20.93 | 2019 | |
| Botanix Sb INC | $18.90 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $17.03 | 2024 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $16.43 | 2019 | |
| Biofrontera INC. | $13.75 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Merz North America, INC. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.